A recent study found that the maternal use of antibiotics during pregnancy appears to increase the risk of otitis media and the placement of ventilation tubes in the offspring, particularly when administered later in the pregnancy.
Recent data has revealed the live attenuated influenza vaccine (LAIV), also known as the “nasal spray” vaccine, to be grossly ineffective, leading to the ACIP’s decision not to recommend its usage. As such, healthcare providers must be judicious in their choice of influenza vaccine with their patients.
A recent study in preterm infants found that exposure to midazolam, a commonly used sedative in the neonatal intensive care unit (NICU), was associated with macro- and microstructural alterations in hippocampal development and poorer outcomes consistent with hippocampal dysmaturation.
Maintaining the currently recommended vaccination schedule of influenza, pneumococcal conjugate, and diphtheria/tetanus/acellular pertussis vaccines in young children as put forth by the Centers for Disease Control and Prevention is likely the best way to manage immunization in this patient population despite the slightly increased risk for febrile seizure.
Although still underused among available diagnostic procedures, nasal cytology is viewed by many specialists as an indispensable adjunctive diagnostic exam that clinicians can and should use more often to optimally diagnose, treat, and manage the myriad of nasal disorders and diseases occurring in pediatric patients.
New research suggests that the use of small-particle inhaled corticosteroids as a first-line or step-up therapy for uncontrollable asthma in children would be more helpful in clearing symptoms and preventing exacerbations than traditional treatment approaches such as large-particle inhaled corticosteroids with or without the addition of long-acting beta 2 agonists.
The currently recommended childhood immunization schedule put forth by the Centers for Disease Control and Prevention (CDC) is designed to protect infants and young children from 14 harmful and potentially deadly diseases before a child’s second birthday.
Women who receive the prophylactic bivalent human papilloma virus (HPV) vaccine within 90 days of pregnancy are not at an increased risk for miscarriage, underscoring the safety of the vaccine. The proven safety of the bivalent HPV vaccine should quell the concerns of women and their health care practitioners.
The CDC now recommends that high-risk infants undergo postvaccination serologic testing between 9 and 12 months, updated from 9-18 months. The new vaccination interval can better cover at risk infants from HBV infection and also help ensure a higher adherence to the immunoprophylaxis protocol.